Results 151 to 160 of about 87,598,632 (299)

Disease Course After Anti‐CD20 Discontinuation in Secondary Progressive Multiple Sclerosis—A Multicenter Long‐Term Longitudinal Study

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To describe long‐term outcomes after anti‐CD20 discontinuation in selected patients with secondary progressive multiple sclerosis (SPMS) who remained without subsequent disease‐modifying therapy (DMT). Methods We retrospectively analyzed data from four centers in Austria and Switzerland.
Ferdinand Otto   +12 more
wiley   +1 more source

Annual Report - Marine Biological Laboratory, 1950

open access: yes, 1951
Annual report of the Marine Biological Laboratory in Woods Hole. 1950.
Marine Biological Laboratory (Woods Hole MA)
core  

Anti‐CD20 Discontinuation Versus Continuation in People Aged Over 50 With Non‐Active Multiple Sclerosis

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To determine whether discontinuing anti‐CD20 therapy in people with relapsing‐onset MS aged over 50 is associated with an increased risk of relapse, inflammatory activity, confirmed disability accrual, and serious infection compared with continuing therapy.
Alexia Moukhine   +40 more
wiley   +1 more source

Exposure to biological agents used in Polish enterprises: Analysis of data derived from the national register of biological agents

open access: yesMedycyna Pracy, 2011
<p>Introduction: The National Register of Biological Agents at Work and the National Information Centre for Biological Agents Present at Workplaces were established in the Nofer Institute of Occupational Medicine in 2005. The National Information Centre carries out consultation and education activities concerning occupational exposure and
openaire  

Annual Report - Marine Biological Laboratory, 1941

open access: yes, 1942
Annual report of the Marine Biological Laboratory in Woods Hole. 1941.
Marine Biological Laboratory (Woods Hole MA)
core  

Safety and Efficacy of GLP‐1 Receptor Agonists in Adults With Epilepsy, Obesity, and Type 2 Diabetes

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Managing obesity in patients with epilepsy is complicated by the weight‐gaining properties of essential antiseizure medications (ASMs) such as valproate and pregabalin. We evaluated the safety and efficacy of initiating glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) in this population.
Hyoshin Son   +3 more
wiley   +1 more source

Occupational exposure to biological agents in Polish paramedics: a narrative review

open access: yesDisaster and Emergency Medicine Journal, 2021
Agnieszka Gonczaryk   +4 more
openaire   +4 more sources

Advances in Nanotoxicology: Health and Safety. [PDF]

open access: yesNanomaterials (Basel)
Krasteva N, Georgieva M.
europepmc   +1 more source

Annual Report - Marine Biological Laboratory, 1980

open access: yes, 1981
Annual report of the Marine Biological Laboratory in Woods Hole. 1980.
Marine Biological Laboratory (Woods Hole MA)
core  

Home - About - Disclaimer - Privacy